Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts - Wikidata - wikimedia - TriplyDB

Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts

Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts

http://www.wikidata.org/entity/Q34109953

about

TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors New Strategies for the Treatment of Solid Tumors with CAR-T Cells Regulation of IL-10 and IL-12 production and function in macrophages and dendritic cells Stromal Fibroblast in Age-Related Cancer: Role in Tumorigenesis and Potential as Novel Therapeutic Target The impact of the myeloid response to radiation therapy Genetic engineering with T cell receptors Advances in the treatment of metastatic melanoma: adoptive T-cell therapy Identification of the genomic insertion site of Pmel-1 TCR α and β transgenes by next-generation sequencing Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination T-cell receptor gene therapy--ready to go viral?Enhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case study Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance Induction of Wnt-inducible signaling protein-1 correlates with invasive breast cancer oncogenesis and reduced type 1 cell-mediated cytotoxic immunity: a retrospective study Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1 Strategies to genetically engineer T cells for cancer immunotherapy.In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes Localized interleukin-12 delivery for immunotherapy of solid tumours.The basic principles of chimeric antigen receptor design.CAR-modified T-cell therapy for cancer: an updated review.Mesenchymal stem cells genetically modified by lentivirus-mediated interleukin-12 inhibit malignant ascites in mice.Immunotherapy for metastatic solid cancers Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions A quantitative systems approach to identify paracrine mechanisms that locally suppress immune response to Interleukin-12 in the B16 melanoma model.An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.Genetically engineered T cells for the treatment of cancer.Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment.miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines.Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.Targeting the tumor microenvironment to enhance antitumor immune responses Mouse model for pre-clinical study of human cancer immunotherapy.Personalized cell transfer immunotherapy for B-cell malignancies and solid cancers IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors.The PDL1-PD1 axis converts human TH1 cells into regulatory T cells.Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma Anti-Tumor Effects after Adoptive Transfer of IL-12 Transposon-Modified Murine Splenocytes in the OT-I-Melanoma Mouse Model.Interleukin-12 in patients with cancer is synthesized by peripheral helper T lymphocytes Evaluation of γ-retroviral vectors that mediate the inducible expression of IL-12 for clinical application.Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.A systematic analysis of experimental immunotherapies on tumors differing in size and duration of growth

P2860

Q21131200-DD1E7281-E330-484C-B876-536E6D78F790 Q26741260-05AC3C3C-B89E-4349-9A20-FF2CACA81DF8 Q26748500-332A9C06-5E33-4570-87E3-624CB0854696 Q26766184-B9E1F784-BB07-43A9-A7FB-CA371D0F921F Q26797288-2E0FCACB-6DB4-468D-9EFD-54BF4EB7CB5E Q26851643-B2B93A74-F3F3-49F1-9000-F0449E39F732 Q26995677-6619D00D-6A44-4B0D-9C44-BC8450F59136 Q27027803-84107A69-7F62-4C2D-8F76-CAD9A7F640F7 Q27334215-D075D1AB-E586-4D0A-A933-CBFA64C49B5B Q28068378-922A9240-CAFA-4F24-9755-7EE0ED39323D Q28081611-03FC02D6-02A1-47A9-9C8B-9DAEFA8526BC Q28084489-78387CBA-DBD3-45B5-A3EA-432463E952BA Q28269352-B38DDE0D-01F6-4A1C-9803-00BE909A3680 Q28538654-53208874-C630-42E8-9ED0-E122E513A0DB Q29616128-FD0FF899-3DA8-4B2B-92D8-30E268646EFC Q33655849-F7FEF086-BE37-463C-BEDE-56C10546C031 Q33716478-2C5E0CF6-A42F-4B8D-8BF3-30105B68DD20 Q33982352-A686AFB0-39A3-4F30-903B-3966C957BA9D Q34036213-6A6F1D8A-FB49-4D08-91FA-15A2D3075EC3 Q34044213-C42ED5B9-76A1-4CEF-AFCA-BF961959F206 Q34119602-CDA597BD-D4CF-4493-A264-BBBA49BC203B Q34219970-5408256B-B682-4DFF-B046-3CFEA74C21A1 Q34248531-6CBB1914-D194-4923-AA1F-CD08D59491DE Q34331673-DCF17B6B-A026-4B9D-AA3D-1CD5F0DEAC3D Q34361976-7F67BDB5-4085-4929-9312-B94FE48A91DE Q34645898-6998934F-2035-47EE-9992-E773BA75B111 Q34757266-34D1C6BC-F525-45ED-8106-A620DC41AEF2 Q34985536-7DEC1C5F-885C-487C-BAAF-D5E6BCF85966 Q35001971-154C88D4-EACE-457E-90C4-E69001889A77 Q35176307-655C8D86-2F57-42E9-A884-2FBC65EAEC48 Q35181705-6CD9CA74-D95D-496F-B416-8E79F48C7E68 Q35568556-898E016E-BD99-4BA8-B611-27125B98593A Q35578622-A86DBBDA-90A2-4F73-AF80-8CCE748C4667 Q35607698-186DA3CD-20C9-4BA2-8908-6280F935EB0D Q35613148-E5E9CABB-C62A-4148-BB21-D25B9A62BE64 Q35810197-70037A53-7F3E-42FC-83AF-B16B5806658F Q35944067-CB53A94D-620F-4B12-97E9-8E20118561BA Q35982211-DE9E86DA-BCF7-46B7-935C-9DD68E941D17 Q35986612-90494CEA-2FEB-468A-B4CD-6F06EF0D513B Q36038477-46E0202D-92D5-4996-B01F-0DBF91D2D9D1

P2860

Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts

http://www.wikidata.org/entity/Q34109953

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Tumor-specific CD8+ T cells ex ...... ancers in lymphodepleted hosts

@ast

Tumor-specific CD8+ T cells ex ...... ancers in lymphodepleted hosts

@en

Tumor-specific CD8+ T cells ex ...... ancers in lymphodepleted hosts

@nl

type

label

Tumor-specific CD8+ T cells ex ...... ancers in lymphodepleted hosts

@ast

Tumor-specific CD8+ T cells ex ...... ancers in lymphodepleted hosts

@en

Tumor-specific CD8+ T cells ex ...... ancers in lymphodepleted hosts

@nl

prefLabel

Tumor-specific CD8+ T cells ex ...... ancers in lymphodepleted hosts

@ast

Tumor-specific CD8+ T cells ex ...... ancers in lymphodepleted hosts

@en

Tumor-specific CD8+ T cells ex ...... ancers in lymphodepleted hosts

@nl

P1433

Q34109953-B439235A-00C6-43BF-B048-04A8F78AB3A8

P1476

Q34109953-45B67C35-AFF1-4EFE-973F-616BBA933D38

P2093

Q34109953-0DF7A512-55C2-44DD-AB19-5D2ABBA386CD

Q34109953-39BC9D3A-0D2C-402A-986E-7C3CA42C2D8A

Q34109953-39D2688E-7CFF-433D-A0C3-776BA84D858C

Q34109953-4229492F-2861-4BBF-8121-BC802B92E512

Q34109953-4A217E11-99FC-45BD-832E-EA748919599C

Q34109953-5343325C-9515-4D88-917C-E4F739637398

Q34109953-632FE246-E3BA-406C-A7DC-6FF49C22F5C3

Q34109953-9D76F4EB-A886-4D7F-BD69-25BF2C35010B

Q34109953-A606EB8B-4D0F-4518-BA0A-B90DD181ED69

Q34109953-AA86A06C-DD35-40D4-9A25-050451E8780A

P2860

Q34109953-023BEF4C-72C0-4640-9341-4D59A2A59E57

Q34109953-03D98B3B-84B5-4DC1-AAB8-6B5F4E5C8526

Q34109953-0AC39859-A187-419F-82C8-8A8856AA31D8

Q34109953-1334700F-AD7C-4E95-9109-654284448335

Q34109953-198603EB-FDA7-422B-8A32-BDBA59B6FD09

Q34109953-24CE8119-EC3B-4DEF-8864-E6017A2D0A45

Q34109953-3913E21D-7F1E-4FB5-827F-888840E10CB7

Q34109953-4164449D-2AF5-4177-9142-13DBE1DA67BA

Q34109953-43E559A7-B966-418B-91C8-75A5A0CB33C0

Q34109953-4B37DE30-23B6-4D55-9C82-8749507CE959

P304

Q34109953-EDED1870-9D80-45F1-A7F5-133C65293D4D

P31

Q34109953-ED2F2467-F047-4E3B-ABED-5B348B061897

P356

Q34109953-57FD46D0-FD0C-48B7-B4D6-4434D16412FF

P407

Q34109953-9AAF9167-C636-4C13-A5DF-30A6A2DF3D1B

P433

Q34109953-1B8F8879-DF42-4EEC-B914-83F4D8D69814

P478

Q34109953-382A8338-48D7-4506-AC73-5BFC21D258D2

P50

Q34109953-73B90EA9-E51D-46E6-B5AB-CBADDF593CBF

P577

Q34109953-961AD766-6C08-4EC4-9AF5-4A11412C6933

P5875

Q34109953-1598DD9A-A384-4C6A-9325-C78025900310

P698

Q34109953-B8A17ADF-330F-4B15-9EAC-5CEF912ACB96

P921

Q34109953-40be95d6-b5db-4249-a41b-c48d9ea058c4

P932

Q34109953-0E164207-8641-4E43-BB70-A7CBAC25ED95

P356

0008-5472.CAN-10-0735

P1433

Cancer Research

P1476

Tumor-specific CD8+ T cells ex ...... ancers in lymphodepleted hosts

@en

P2093

Andrea Boni

http://www.w3.org/2001/XMLSchema#string

Andrew Kaiser

http://www.w3.org/2001/XMLSchema#string

Giorgio Trinchieri

http://www.w3.org/2001/XMLSchema#string

Ling Zhang

http://www.w3.org/2001/XMLSchema#string

Luca Gattinoni

http://www.w3.org/2001/XMLSchema#string

Luis Sanchez-Perez

http://www.w3.org/2001/XMLSchema#string

Nicholas P Restifo

http://www.w3.org/2001/XMLSchema#string

Pawel Muranski

http://www.w3.org/2001/XMLSchema#string

Richard A Morgan

http://www.w3.org/2001/XMLSchema#string

Robert N Reger

http://www.w3.org/2001/XMLSchema#string

P2860

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells

Myeloid-derived suppressor cells as regulators of the immune system

Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages

Immunosuppressive networks in the tumour environment and their therapeutic relevance

Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice.

Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine.

Interleukin-12 as an adjuvant for cancer immunotherapy.

P304

6725-6734

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-10-0735

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-07-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45278441

http://www.w3.org/2001/XMLSchema#string

P698

20647327

http://www.w3.org/2001/XMLSchema#string

P921

P932

2935308

http://www.w3.org/2001/XMLSchema#string